ArticleJournal of medicinal chemistry2016

Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.

Kayla J Temple et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.